Stocks · News reference
Acumen Pharmaceuticals announced it will present three poster presentations regarding its Phase 2 ALTITUDE-AD trial of sabirnetug at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Following the discontinuation of Acumen Pharmaceuticals' lead drug candidate, BTIG maintained a Buy rating on the stock while significantly reducing its price target.
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.
Acumen Pharmaceuticals is discontinuing the development of its lead clinical candidate, sabirnetug (ACU193), following the failure of a Phase 2 clinical trial to meet its primary endpoint.
Filed: 2026-10-30 AccNo: 0001628280-26-068425 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits